18F-DOPA PET/CT Imaging Optimization
What You Need to Know Before You Apply
What is the purpose of this trial?
A single centre non-randomized, non-blinded phase III prospective cohort study of 18F-DOPA PET/CT imaging in specific patient populations:1. Pediatric patients (less than 18 years old) with congenital hyperinsulinism.2. Pediatric patients (less than 18 years old) with neuroblastoma.3. Pediatric (less than 18 years old) or Adult patients (18 or older) with known or clinically suspected neuroendocrine tumor.4. Adult patients (18 or older) with a clinical suspicion of Parkinson's disease or Lewy body dementia.5. Pediatric (less than 18 years old) or Adult patients (18 or older) with brain tumors.Image optimization (the primary study objective) and gallbladder activity pattern (the secondary objective) will be evaluated.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is 18F-DOPA PET/CT imaging safe for humans?
How does the drug 18F-DOPA differ from other treatments for neuroendocrine tumors?
18F-DOPA is unique because it is a radiotracer used in PET/CT imaging to detect and manage neuroendocrine tumors by mimicking the natural amino acid L-DOPA, which is taken up by specific transporters in the body. This allows for precise imaging of tumor activity, which is different from traditional treatments that may not provide such detailed visualization.15678
What data supports the effectiveness of the drug 18F-DOPA in the clinical trial?
Research shows that 18F-DOPA PET imaging is useful for detecting and managing brain tumors, movement disorders, and neuroendocrine tumors. It has been used effectively in imaging for Parkinson's disease and carcinoid tumors, helping to locate tumors more accurately than some traditional methods.125910
Who Is on the Research Team?
Jonathan Abele, MD
Principal Investigator
University of Alberta
Are You a Good Fit for This Trial?
This trial is for children and adults with certain conditions like congenital hyperinsulinism, neuroendocrine tumors, brain tumors, Parkinson's disease or Lewy body dementia. It excludes pregnant individuals, those over 225 kg, patients who can't lie flat for the scan duration or give consent, and young kids who can't be sedated safely.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Imaging and Assessment
Participants receive an 18F-DOPA PET/CT scan to assess image optimization and gallbladder activity patterns
Follow-up
Participants are monitored for safety and effectiveness after imaging
What Are the Treatments Tested in This Trial?
Interventions
- 18F-DOPA
- Furosemide Injection
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alberta
Lead Sponsor